ISV-403

DRUG2 trials

Sponsors

Bausch & Lomb Incorporated

Conditions

Acute Bacterial ConjunctivitisBacterial Conjunctivitis

Phase 2

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

CompletedNCT00622908

Bausch & Lomb IncorporatedBacterial Conjunctivitis

Start: 2004-12-31End: 2005-06-30Updated: 2015-03-24

Phase 3

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

CompletedNCT00347932

Bausch & Lomb IncorporatedAcute Bacterial Conjunctivitis

Start: 2006-06-30End: 2007-11-30Updated: 2015-03-24

Related Papers

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%

PLoS ONE2020-08-259 citations

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.

2009-05-0160 citations

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.

2009-03-0164 citations